Bio Path reported 13.65M in Cash and Equivalent for its fiscal quarter ending in September of 2022.





Cash And Equivalent Change Date
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
Baxter International USD 1.98B 175M Sep/2026
Bio Path 13.65M 3.37M Sep/2022
Cipla INR 16.59B 6.41B Sep/2026
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 10.28M 2.15M Jun/2026
CSL USD 2.16B 633M Jun/2025
Grifols EUR 979.78M 334.84M Dec/2024
Karyopharm Therapeutics USD 90.85M 30.31M Mar/2026